



30<sup>th</sup> May, 2018

Scrip Code: 541299

**Outcome of Board Meeting**

In continuation of our Letter dated May 21, 2018, we wish to inform you that the Board of the Company at its meeting held today, inter alia has transacted the following:

- a) The Board has approved the Audited Financial Results for the half year and year ended March 31, 2018.  
Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose the following:
  - i. Statement showing Audited Financial Results for the half year and year ended March 31, 2018.
  - ii. Auditors Report on Financial Results of the Company for the year ended 31<sup>st</sup> March, 2018.


Kindly take the same on record and acknowledge.

Thank You  
Yours Faithfully

For Dr Lalchandani Labs Limited



Arjan Lalchandani  
Managing Director  
DIN-07014579



**AASM & Co.**  
**Chartered Accountants**



To  
The Board of Directors of  
Dr Lalchandani Labs Limited

We have audited the yearly Standalone financial results of Dr Lalchandani Labs Limited for the year ended 31<sup>st</sup> March, 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, and collection of evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion. In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the year ended 31<sup>st</sup> March, 2018.

For AASM & Co.  
Chartered Accountants  
FRN: 030481N

Ashish Arora  
(Partner)  
Membership No.: 516241

Place: New Delhi

Date: 30<sup>th</sup> May, 2018



**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended	Previous Year Ended
		31.03.2018	31.03.2017
1	<b>Shareholders' Funds</b>	293.31	91.92
	(a) Share Capital	39.98	-
	(b) Reserves and Surplus	-	-
	(c) Money received against share warrants	-	-
	<b>Sub-total-Shareholders' Funds</b>	<b>333.29</b>	<b>91.92</b>
2	<b>Share application money pending allotment</b>		
3	<b>Non Current Liabilities</b>	182.37	162.10
	(a) Long Term Borrowings	2.39	-
	(b) Deferred Tax Liability	-	-
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	<b>Sub-total-Non Current Liabilities</b>	<b>184.76</b>	<b>162.10</b>
4	<b>Current Liabilities</b>	5.06	14.93
	(a) Short Term Borrowings	68.17	37.66
	(b) Trade Payables	21.87	69.78
	(c) Other Current Liabilities	7.03	-
	(d) Short Term Provisions	-	-
	<b>Sub-total-Current Liabilities</b>	<b>102.13</b>	<b>122.37</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>620.18</b>	<b>376.39</b>
II	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(a) Fixed Assets	205.36	88.80
	(i) Tangible assets	0.45	-
	(ii) Intangible assets	24.10	22.59
	(b) Non Current Investments	-	-
	(c) Long Term Loans & Advances	-	-
	(d) Other Non Current Assets	8.25	10.24
	<b>Sub-total-Non Current Assets</b>	<b>238.16</b>	<b>121.63</b>



**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

*Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	Previous Year Ended
		31.03.2018	31.03.2017
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	27.12	18.47
	(b) Inventories	112.06	60.94
	(c) Trade Receivables	90.86	5.48
	(d) Cash & cash equivalents	107.89	113.00
	(e) Short Term Loans & Advances	44.09	56.87
	(f) Other Current Assets	<b>382.02</b>	<b>254.76</b>
	<b>Sub-total-Current Assets</b>	<b>620.18</b>	<b>376.39</b>
	<b>TOTAL ASSETS</b>		

For Dr Lalchandani Labs Limited,



Dr. Arjan Lalchandani  
(Managing Director DIN: 07014579)

New Delhi  
30-May-18



**AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH, 2018**

Amount Rs. in Lacs

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2018	30.09.2017	31.03.2017	31.03.2018	31.03.2017
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	229.59	264.86	225.77	494.45	452.02
II	Other Income	1.78	0.92	5.78	2.70	8.93
III	<b>Total Revenue(I+II)</b>	<b>231.37</b>	<b>265.78</b>	<b>231.55</b>	<b>497.15</b>	<b>460.95</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	50.03	60.13	86.47	110.17	206.14
	(b) Purchases of stock in trade	54.21	58.23	92.24	112.44	207.38
	(c) Changes in inventories of finished goods, work in progress and stock in trade	4.18	1.91	5.77	2.27	1.24
	(d) Employee benefits expense	41.91	28.87	22.81	70.78	35.97
	(e) Finance Cost	12.45	13.74	18.81	26.19	35.83
	(f) Depreciation and amortisation expense	13.08	-	16.93	13.08	16.93
	(g) Other Expenses	98.35	61.22	82.26	159.57	95.35
	<b>Total Expenses</b>	<b>215.82</b>	<b>163.96</b>	<b>204.46</b>	<b>379.78</b>	<b>390.22</b>
V	Profit before exceptional and extraordinary items and tax (III - IV)	15.55	101.82	27.09	117.36	70.73
VI	Exceptional Items			-	-	-
VII	Profit extraordinary items and tax (V - VI)	15.55	101.82	27.09	117.36	70.73
VIII	Extraordinary Items			-	-	-
IX	Profit before tax (VIII - VIII)	15.55	101.82	27.09	117.36	70.73
X	Tax Expenses :					
	(1) Current Tax	6.83	25.31	8.37	32.14	21.86
	(2) Deferred Tax	2.39	-	-	2.39	-
XI	Profit / (Loss) from Period from continuing optstions (VII -VIII)	6.33	76.51	18.72	82.84	48.87
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-



**AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH, 2018**

*Amount Rs. in Lacs*

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2018	30.09.2017	31.03.2017	31.03.2018	31.03.2017
		Audited	Unaudited	Audited	Audited	Audited
XIV	Profit / (Loss) from Discontinuing oprtstions (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	6.33	76.51	18.72	82.84	48.87
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	0.22	5.45	2.04	2.82	5.32
	(b) Diluted (Rs.)	0.22	5.45	2.04	2.82	5.32
	<b>(iii) Investor Complaint Pending</b>					
	Pending at the beginning of the half year					
	Received During the Half Year					
	Disposed of during the half year					
	Remainig unresolved at the end of the period					

**Notes:**

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 30th May, 2018
2. There were no investor complaints received / pending as at 30th May, 2018
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
4. The business of Dr. A Lalchandani Pathology Laboratories (Partnership firm) was taken over by Dr Lalchandani Labs Limited on 31st August 2017.
5. We have booked provision for income tax on profits earned by Dr. A Lalchandani Pathology Laboratories (Partnership firm) for the period ended 31/03/2017 and 31/8/2017.

For Dr Lalchandani Labs Limited,



(Dr. Arjan Lalchandani)

Managing Director (DIN: 07014579 )

New Delhi

30-May-18